Use the Search Fields to Find Information
Page 53 of 360
THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner
Abstract Glioblastoma (GBM) is the most frequent malignant tumor of the central nervous system in humans with a median survival time of less than 15
April 30, 2024
THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation
Please use this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S0165178123005930 Abstract Prenatal infections and cannabis use during adolescence are well-recognized risk factors for schizophrenia. As inflammation and
December 6, 2023
THC Exposure is Reflected in the Microstructure of the Cerebral Cortex and Amygdala of Young Adults
Abstract The endocannabinoid system serves a critical role in homeostatic regulation through its influence on processes underlying appetite, pain, reward, and stress, and cannabis has
May 31, 2024
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
Please use this link to access this publication. Abstract Cannabis use has been associated with an increased risk to develop schizophrenia as well as symptom
September 4, 2024
THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways
Please use this link to access this publication. Abstract Clinical and pre-clinical evidence demonstrates divergent psychotropic effects of THC vs. CBD. While THC can induce
March 25, 2024
THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet
Abstract Background: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome, which often includes obesity, diabetes, and dyslipidemia. Several studies in mice and humans
February 12, 2024
Text message-delivered cannabis use disorder treatment with young adults: A large randomized clinical trial
Please use this link to access this publication. Abstract Background Two scientific and clinical challenges for treating cannabis use disorder (CUD) are developing efficacious treatments
February 15, 2026
Tetrahydrocannabinol vape-associated cannabis arteritis in a patient with minimal tobacco exposure
Abstract Thromboangiitis obliterans (TAO) is an inflammatory vasculopathy that often presents in young men with substantial tobacco use. Cannabis arteritis is the cannabis-associated counterpart, but
February 8, 2026
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study
Please use this link to access this publication. Abstract Background & Aims Delta-9-tetrahydrocannabinol (THC) is the most abundant cannabinoid from the plant Cannabis sativa. There is only equivocal
August 5, 2024
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
Please use this link to access this publication. Abstract Objective: To determine whether differences in disability status, spasticity severity, and spasticity duration at treatment start in
July 1, 2024
Page 53 of 360